Oslo, Norway 20, February 2025

In connection with the release of the results for the full year and fourth
quarter 2024, Oncoinvent invites to the following events:

Thursday 27 February 2025
07.30 CET
Release of stock exchange notification. Press release, quarterly report and
presentation will be available on www.oncoinvent.com.

10.00 CET
Live streamed of quarterly presentation in English. A webcast will be available
for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A
through the MS Teams Webinar.

About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin in a clinical
development program in two indications. Currently two phase 1/2a trials and one
randomized phase 2 trial are ongoing in the US, UK and Europe. More than 150
patients with peritoneal carcinomatosis, secondary to ovarian and colorectal
cancer, will be enrolled in the current program. Preliminary clinical efficacy
data are highly encouraging, and no serious toxicity or safety concerns have
been reported to date. The Oncoinvent team consists of approx. 30 employees and
runs a state-of-the-art manufacturing facility to produce drug products for
clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth
Oslo.


Forward-Looking Statements
All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These
forward-looking statements represent Oncoinvent's expectations as of the date of
this press release, and Oncoinvent disclaims any obligation to update the
forward-looking statements. These forward-looking statements are subject to
known and unknown risks and uncertainties that may cause actual results to
differ materially, including with respect to whether the results of clinical or
other studies will support the use of our product offerings, the impact of
results of such studies, our expectations of the reliability, accuracy and
performance of our tests, or of the benefits of our tests and product offerings
to patients, providers and payers.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com 

Tore Kvam, Chief Financial Officer 
Email: kvam@oncoinvent.com